Oncology & Cancer

Tirbanibulin superior to placebo for actinic keratosis

(HealthDay)—Tirbanibulin is superior to vehicle at two months for the treatment of actinic keratosis, but almost half of patients who had a complete response experienced recurrence of lesions at one year, according to a ...

Diseases, Conditions, Syndromes

Skin diseases are more common than we think

Skin diseases are ranked as the fourth most common cause of human illness, but many affected people do not consult a physician. A new Journal of the European Academy of Dermatology and Venereology study estimates the prevalence ...

Immunology

New topical immunotherapy effective against early skin cancer

A combination of two topical drugs that have been in use for years triggers a robust immune response against precancerous skin lesions, according to a new study. The research, from Washington University School of Medicine ...

Diseases, Conditions, Syndromes

Poor persistence/Adherence with long-term topical AK treatment

(HealthDay)—A considerable proportion of patients with actinic keratosis (AK) receiving long-term topical treatment have poor persistence or adherence, according to a study published online April 18 in the British Journal ...

page 1 from 2